BioMarin Pharmaceutical's Management Presents at 2013 Deutsche Bank BioFEST Conference
Alright, thank you all for joining us. For those of you on the webcast, my name is Robyn Karnauskas.
Mon Dec 02, 2013
Scioderm Appoints Orphan Product Executives To Board Of Directors
As Chairman & CEO of NASDAQ listed Amicus Therapeutics, John brings a significant rare and orphan disease experience to Scioderm, in addition to his in depth transactional and public sector market experience.
Fri Nov 29, 2013
Stock Analysts' Upgrades for November, 29th (AIRM, BERY, BMRN,...
Zacks currently has $56.70 price target on the stock. was upgraded by analysts at Zacks from an underperform rating to a neutral rating.
BioMarin Pharmaceutical Upgraded to Hold at TheStreet
The analysts wrote, "Biomarin Pharmaceutical has been upgraded by TheStreet Ratings from sell to hold.
Tue Nov 26, 2013
BioMarin: Where Biotech and Rodney Dangerfield Cross Paths
Last week an FDA panel all but guaranteed that Vimizim -- BioMarin Pharmaceutical's new drug for Morquio IV syndrome -- will be approved without any label restrictions.
Dan Spiegelman, CFO of BioMarin, to Present at the Deutsche Bank 2013 BioFest Conference in Boston
BioMarin Pharmaceutical Inc. today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer at BioMarin, will present a company update at the Deutsche Bank 2013 BioFest Conference on Tuesday, December 3, 2013 at 9:35 a.m. ET.
Thu Nov 21, 2013
BioMarin Seen Luring $13 Billion Takeover Bid: Real M&A
BioMarin Pharmaceutical Inc. may draw bidders to the biggest biotechnology deal in three years after its most promising rare-disease drug came one step closer to U.S. regulatory approval this week.
Five Star Equities Issues New Research Reports on ADT, BMRN, DVN and...
ADT Corp. shares increased 2.41 percent to close at $43.84 a share Wednesday. The stock traded between $43.05 and $46.05 on volume of 7.98 million shares traded.
Wed Nov 20, 2013
BioMarin Pharmaceutical Price Target Raised to $78.00 at Leerink Swann
The firm currently has an "outperform" rating on the stock. Leerink Swann's price objective indicates a potential upside of 12.81% from the company's current price.
Cisco Systems, Inc. (NASDAQ:CSCO) and BioMarin Pharmaceutical Inc....
Growing Stock Report expands its NASDAQ Active Stock Weekly Watch List adding Cisco Systems, Inc. and BioMarin Pharmaceutical Inc. .
Investor's Business Daily
BioMarin Wins FDA Panel Vote, Cuts Deal With Myriad
The disease, which retards growth and causes skeletal deformities, is currently treated only with palliative measures, but Vimizim provides enzymes that sufferers naturally lack, and so slows its progress.
The Washington Post
U.S. Stock-Index Futures Slip Before Fed Minutes, Economic Data
U.S. stock-index futures slipped before the Federal Reserve releases minutes of its latest policy meeting later today, and as investors await data on retail and existing home sales.
Tue Nov 19, 2013
Research Alert-Biomarin Pharmaceutical: Leerink Swann raises target price
BioMarin Pharmaceutical Inc : * Leerink Swann raises target price to $78 from $76; rating outperform For a summary of rating and price target changes on U.S. companies: Reuters Eikon users, click on Reuters 3000Xtra users, double-click Thomson ONE users, type in RT/RCH/US For a summary of rating and price target changes on Canadian companies: ... (more)
BioMarin Pharmaceutical Stock Rating Reaffirmed by Wells Fargo & Co.
's stock had its "positive" rating restated by analysts at Wells Fargo & Co. in a research report issued to clients and investors on Tuesday, ARN reports.
FDA Advisory Committee Recommends Approval for BioMarin's Vimizim(TM) ...
BioMarin Pharmaceutical Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration voted in favor of approval of Vimizim for the treatment of Morquio A syndrome, also called Mucopolysaccharidosis Type IVA .
The Motley Fool
Keep an Eye on BioMarin, Amgen, Merck, and AstraZeneca Today
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Mon Nov 18, 2013
BioMarin Pharmaceutical Inc. Release: FDA Posts Briefing Documents...
BioMarin Pharmaceutical Inc. announced today the U.S. Food and Drug Administration posted briefing materials for the November 19, 2013 Endocrinologic and Metabolic Drugs Advisory Committee meeting to review the Vimizima Biologics License Application .
Stocks in Focus: Akorn, Inc.
Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages.
Fri Nov 15, 2013
Groupon, Inc. (NASDAQ:GRPN) and BioMarin Pharmaceutical Inc....
Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding Groupon, Inc. and BioMarin Pharmaceutical Inc. .
BioMarin Pharmaceutical Inc. Announces French ATU Granted for...
BioMarin Announces French ATU Granted for Vimizim for the Treatment of Morquio A Syndrome SAN RAFAEL, Calif., Nov. 15, 2013 -- BioMarin Pharmaceutical Inc. announced today that the French National Agency for Medicines and Health Products Safety has granted an Autorisation Temporaire d'Utilisation de cohorte , or Temporary Authorization for Use, for ... (more)